pharmaphorum
DECEMBER 5, 2013
Join a cross-stakeholder panel, including the CEO of Doctors.net.uk, a pharmaceutical industry digital engagement expert and two doctors, to understand areas of mutual interest for doctors engaging with pharma online and the specific types of information and dialogue they are seeking.
Placebo Control
DECEMBER 19, 2013
The Wall Street Journal has an interesting article on the use of “Big Data” to identify and solicit potential clinical trial participants. The premise is that large consumer data aggregators like Experian can target patients with certain diseases through correlations with non-health behavior. Examples given include “a preference for jazz” being associated with arthritis and “shopping online for clothes” being an indicator of obesity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Placebo Control
DECEMBER 4, 2013
(*For certain possibly nonstandard uses of the word "unpublished") This is an odd little study. Instead of looking at registered trials and following them through to publication, this study starts with a random sample of phase 3 and 4 drug trials that already had results posted on ClinicalTrials.gov - so in one, very obvious sense, none of the trials in this study went unpublished.
Placebo Control
SEPTEMBER 25, 2013
Although a few articles on this site are older, I really only began blogging in earnest about 15 months ago. However, I suppose that's long enough that I can count myself as at least somewhat established, and take a moment to welcome and encourage some interesting newcomers to the scene. Bloggers in dank basements their natural habitat. There are 3 relative newcomers that I've found really interesting, all with very different perspectives on drug development and clinical research: Pharmagellan T
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Placebo Control
SEPTEMBER 19, 2013
The authors of the study I blogged about on Monday were kind enough to post a lengthy comment, responding in part to some of the issues I raised. I thought their response was interesting, and so reprint it in its entirety below, interjecting my own reactions as well. There were a number of points you made in your blog and the title of questionable maths was what caught our eye and so we reply on facts and provide context.
Placebo Control
SEPTEMBER 16, 2013
There has been considerable noise coming out of the UK lately about successes in clinical trial enrollment. First, a couple months ago came the rather dramatic announcement that clinical trial participation in the UK had " tripled over the last 6 years ". That announcement, by the chief executive of the Sweet creature of bombast: is Sir John writing press releases for the NIHR?
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Placebo Control
AUGUST 7, 2013
This morning I ran across a bit of a coffee-spitter : in the middle of an otherwise opaquely underinformative press release fromTranscelerate Biopharma about the launch of their Counterfeits flooding the market? Really? "Comparator Network" - which will perhaps streamline member companies' ability to obtain drugs from each other for clinical trials using active comparator arms - the CEO of the consortium, Dalvir Gill, drops a rather remarkable quote: "Locating and accessing these comparators at
Placebo Control
JULY 31, 2013
Results reporting requirements are pretty clear. Maybe critics should re-check their methods? Ben Goldacre has rather famously described the clinical trial reporting requirements in the Food and Drug Administration Amendments Act of 2007 as a “ fake fix ” that was being thoroughly “ignored” by the pharmaceutical industry. Pharma: breaking the law in broad daylight?
Placebo Control
JUNE 21, 2013
Are we looking at our enrollment data in the right way? I will be chairing a session on Tuesday on this topic, joined by a couple of great presenters (Diana Chung from Gilead and Gretchen Goller from PRA). Here's a short preview of the session: Hope to see you there. It should be a great discussion. Session Details: June 25, 1:45PM - 3:15PM Session Number: 241 Room Number: 205B 1.
Placebo Control
JUNE 19, 2013
[ Fair Warning: I have generally tried to keep this blog separate from my corporate existence, but am making an exception for two quick posts about the upcoming DIA 2013 Annual Meeting.] Improving Enrollment in Pediatric Clinical Trials Logistically, ethically, and emotionally, involving children in medical research is greatly different from the same research in adults.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Placebo Control
JUNE 4, 2013
PDUFA V commitments signal a strong commitment to tolerance of open debate in the face of uncertainty. I can admit to a rather powerful lack of enthusiasm when reading about interpersonal squabbles. It’s even worse in the scientific world: when I read about debates getting mired in personal attacks I tend to simply stop reading and move on to something else.
Placebo Control
MAY 30, 2013
Even by the already-painfully-embarrassingly-low standards of clinical trial enrollment in general, patient enrollment in cancer clinical trials is slow. Horribly slow. In many cancer trials, randomizing one patient every three or four months isn't bad at all – in fact, it's par for the course. The most commonly-cited number is that only 3% of cancer patients participate in a trial – and although exact details of how that number is measured are remarkably difficult to pin down, it certainly can'
Expert insights. Personalized for you.
52 
Let's personalize your content